Cat Number: MAB-94467
Conjugate: Unconjugated
Size: 100 ul
Clone: Mib1
Concentration: 1mg/ml
Host: Ms
Isotype: IgG1
Immunogen: Nuclei of the Hodgkin lymphoma cell line L428
Reactivity: Hu

Immunohistochemistry , Western Blot , Flow Cytometry (QC tested), Immunocytochemistry

Purification: Aff. Pur.
Synonyms: KIA, MIB, Marker of proliferation Ki67, MKI67

The mouse monoclonal antibody Ki-67 recognizes Ki-67 antigen, a non-histone nuclear protein expressed exclusively in proliferating cells. Ki-67 antigen is a nuclear Protein can recognize both isoforms with moelcular weight: 345 kDa and 395 kDa.

Form: Liquid
Buffer: Phosphate buffered saline (PBS) solution with 15 mM sodium azide
Storage: Store at 2-8°C. Do not freeze. For longer term store at: -20°C

Immunocytochemistry detection of Ki-67 in U2OS cell line (human osteosarcoma) using monoclonal antibody Ki-67 (green). Cell nuclei stained with DAPI (blue)


Schlüter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD, Gerdes J: The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol. 1993 Nov;123(3):513-22.
Duchrow M, Schlüter C, Key G, Kubbutat MH, Wohlenberg C, Flad HD, Gerdes J: Cell proliferation-associated nuclear antigen defined by antibody Ki-67: a new kind of cell cycle-maintaining proteins. Arch Immunol Ther Exp (Warsz). 1995;43(2):117-21.
Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984 Oct;133(4):1710-5.
Gerdes J: Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. Semin Cancer Biol. 1990 Jun;1(3):199-206.
Gerdes J, Schwab U, Lemke H, Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983 Jan 15;31(1):13-20.